Table 3.

Subgroup analysis of the effects of psilocybin on depression and anxiety.

Variable	BDI				STAI−Trait
	Number of Effect Sizes	95% CI	p−Value	I2 (%)	Number of Effect Sizes	95% CI	p−Value	I2 (%)
Total	11	−	-	-	11	−	−	−
WMD observed	-	−2.589	0.002 *	0	-	−5.906	<0.001 *	0
		(−4.207 to −0.971)				(−7.852 to −3.960)
WMD adjusted	-	−2.589	-	-	-	−5.906	-	-
		(−4.207 to −0.971)				(−7.852 to −3.960)
Dose (mg/kg)	BDI				STAI−Trait
	Number of Effect Sizes	95% CI	p−Value	I2 (%)	Number of Effect Sizes	95% CI	p−Value	I2 (%)
0.2	2	−4.425	0.195	0	2	−4.509	0.208	0
		(−11.118 to −2.269)				(−11.430 to 2.422)
0.3	7	−1.438	0.171	0	7	−6.240	<0.001 *	0
		(−3.498 to 0.622)				(−8.615 to −3.865)
0.4	2	−4.447	0.002 *	0	2	−5.449	0.008 *	0
		(−7.287 to −1.607)				(−9.345 to −1.553)
Time (days) after Psilocybin Administration	BDI				STAI−Trait
	Number of Effect Sizes	95% CI	p−Value	I2 (%)	Number of Effect Sizes	95% CI	p−Value	I2 (%)
1	3	−1.769	0.325	0	2	−4.359	0.067	0
		(−5.290 to 1.752)				(−8.946 to 0.228)
14	2	−1.766	0.432	0	3	−7.258	0.005 *	39.340
		(−6.167 to 2.635)				(−11.330 to −3.184)
35–189	6	−3.024	0.003 *	0	6	−5.854	<0.001 *	0
		(−5.026 to −1.023)				(−8.385 to −3.322)

WMD—weighted mean differences; CI—confidence interval; * Indicates a significant result.